Comparator Drug Sourcing in Canada

Comparator, reference-listed drug, and rescue-supply sourcing for Phase I–IV clinical trials run in Canada

A comparator is the marketed product a trial measures its investigational product against. Getting it wrong is expensive in a way few other supply decisions are: a comparator sourced from the wrong market, with the wrong presentation, or with insufficient shelf life can invalidate a shipment, delay first patient in, or force a protocol amendment. Nexara Health sources comparators, reference-listed drugs, and authorized generics for sponsors, CROs, and academic investigators under Health Canada Drug Establishment Licence #3-002896, from 9 South Landing Dr #116, Winnipeg, MB R4G 0C4, Canada.

We work from the protocol, not from a product name. Country of origin, marketing authorization holder, salt and strength, pack configuration, expiry dating on arrival, and whether the presentation can be blinded or overlabeled are all settled before a purchase order is raised. Where the protocol allows more than one source market, we price each and show the trade-off between cost, lead time, and remaining shelf life.

Standard enquiries are quoted within 24 hours. Rescue sourcing for shortage events, failed deliveries from another vendor, and protocol amendments mid-study is available and is where a licensed Canadian wholesaler with direct market access matters most.

What is included

• Branded comparator and reference-listed drug (RLD) sourcing
• Authorized generics with full manufacturer release documentation
• 40+ regulated source markets including EU, UK, US, Switzerland, Australia, Japan
• Health Canada DEL #3-002896 — licensed importer and wholesaler
• Centralized hub-and-spoke or country-local sourcing models
• GDP-compliant 2–8 °C, −20 °C and −80 °C cold chain with excursion reporting
• Certificate of Analysis, TSE/BSE statements, and full chain of custody
• Placebo manufacture, matched-comparator overlabel, and blinding handoff
• Returns, reconciliation, and witnessed destruction with regulator-ready records

Choosing the source market

Source market selection is the first real decision in comparator sourcing, and it is rarely only about price. A product marketed in Canada, the United States, and Germany may carry three different pack sizes, two different excipient profiles, and materially different remaining shelf life at the point of purchase. If the protocol specifies the reference-listed drug of a particular jurisdiction, that decision is already made and the work becomes availability and export permission. Where the protocol is open, we compare markets on presentation match, export permissibility, lead time, expiry dating, and landed cost.

Canadian-sourced comparators are the shortest route for a Canadian study: no import permit, minimal freight, and a domestic invoice trail. European sourcing widens availability considerably and is usually the answer for products not marketed here. United States sourcing is common for reference-listed drugs where bioequivalence work is intended to support an ANDA. Australian, Swiss, and Japanese sourcing solves specific presentation gaps.

We tell sponsors when a market is a bad idea. Some jurisdictions restrict export of shortage-listed products; some manufacturers refuse open-market sales for clinical use; some presentations exist only in hospital packs that cannot be blinded. Finding that out at quote stage is cheap. Finding it out after the purchase order is not.

Documentation, and why it decides audits

Every comparator shipment leaves with a documentation package built for inspection rather than for the invoice file. It contains the supplier pedigree showing that stock came from the manufacturer, the marketing authorization holder, or an authorized distributor; the batch number and expiry; the Certificate of Analysis where the manufacturer releases one; TSE/BSE and origin statements where the product requires them; import documentation; and the temperature record for cold-chain product.

Chain of custody is unbroken and written down: who held the product, at what temperature, for how long, and who received it at each transfer. For blinded studies we document the handoff to the blinding or packaging facility separately, because that is the point where most traceability gaps appear.

Reconciliation and destruction close the loop. Unused comparator is reconciled against what was shipped, returns are logged, and destruction is witnessed and certificated. Sponsors are asked for exactly these records at close-out, and assembling them retrospectively is far more painful than keeping them as you go.

Cold chain and handling

Cold-chain comparators ship in qualified shippers with continuous monitoring, at 2–8 °C, −20 °C, or −80 °C as the product requires. Loggers are read on arrival and the record joins the batch file. Where an excursion occurs, it is reported rather than absorbed: the sponsor receives the profile, the duration, and the manufacturer's stability position, and the release decision is made on evidence.

Ambient product is not treated as unregulated. Canadian winter and summer transport both present real temperature risk, and comparator shipped ambient still travels under GDP conditions with route-appropriate packaging.

Storage between receipt and dispatch to site happens in our licensed facility under the same monitoring, so there is no unmonitored gap between import and delivery to the depot.

Working with study timelines

Lead time is the number that drives study startup planning, and honest lead times are more useful than optimistic ones. Comparators available in Canada or from European wholesale stock typically deliver in one to three weeks. Products requiring import permits, restricted-market export, or manufacturer allocation run four to eight weeks. Made-to-order presentations and placebo manufacture are scoped case by case.

For multi-year studies we plan resupply against expiry dating rather than against consumption alone, so that stock on site remains usable through the enrollment window. Where a product is at risk of shortage or discontinuation during the study, we say so at contracting time and, where the sponsor agrees, secure a forward position.

Rescue sourcing is a distinct service. When another vendor fails, a manufacturer pulls allocation, or a shortage hits mid-study, the question is not the cheapest source but the fastest compliant one. We quote those separately and clearly.

Frequently asked questions

What is comparator drug sourcing?

Comparator sourcing is the procurement of a marketed reference product — the active comparator or reference-listed drug — used alongside the investigational product in a clinical trial. It must come from an authorized supply chain with documented pedigree, batch, expiry, and storage history.

Is Nexara licensed to import comparator drugs into Canada?

Yes. Nexara Health holds Health Canada Drug Establishment Licence #3-002896 covering import, wholesale, and storage. Controlled substances scheduled under the CDSA are handled only under the applicable separate authorization.

How fast can a comparator be sourced?

Quotes return within 24 hours for standard requests. Delivery is typically one to three weeks for products available in Canada or from European or United States stock, and four to eight weeks where import permits, restricted markets, or manufacturer allocation apply.

Which countries do you source comparators from?

Over 40 regulated markets, most commonly the United States, United Kingdom, Germany, France, Spain, Italy, the Netherlands, Switzerland, Australia, and Japan, plus authorized generics from India where the manufacturer provides full release documentation.

Do you handle cold chain comparators?

Yes — 2–8 °C, −20 °C and −80 °C, in qualified shippers with continuous temperature monitoring, logger download on receipt, and formal excursion reporting rather than silent acceptance.

Can you provide a market assessment before we commit?

Yes. Before a purchase order we can provide availability by country, indicative pricing, expected shelf life on arrival, export restrictions, and the regulatory pathway for each candidate source market.

Do you support blinding, overlabeling, and placebo?

We supply comparator into the sponsor's blinding or packaging partner with the chain of custody documented at handoff, and can arrange matched placebo manufacture and overlabel through qualified partners where the protocol requires it.

What happens to unused comparator at study close-out?

Unused stock is reconciled against what was shipped, returns are logged against the original batch records, and destruction is witnessed and certificated so the close-out file matches the shipping file.

Related pages

• Clinical Trial Supply Canada
• Comparator sourcing guide
• Named Patient Supply Canada
• Cold Chain Logistics
• Import & Export Services
• Pharmaceutical Wholesaler Canada